The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its legacy within the broader market now triggers questions about potential yields . Generic versions are undercutting exclusivity , leading to worries that investing in companies closely tied to Viagra's former influence could be a dangerous move